Table 1.
Study characteristics.
| Study | Source of Patients | No. of Patients (n) | Histology | Stage | Testing Method | KRAS G12C Mutation Frequency (%) |
KRAS-Comutations (%) | Median Follow-Up Time (Months, Range) | Survival Parameters | NOS Score | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TP53 | STK-11 | KEAP-1 | Outcome | Adjusted Variables | |||||||||
| Arbour, 2021 [36] | USA | 772 | NSCLC | IIIB-IV | NGS-MSK IMPACT assay | 46 | 41.8 | 28.4 | 23.4 | 13.8 | OS | NA | 8 |
| Aredo, 2019 [37] | USA | 186 | NSCLC | I-IV | NGS- STAMP assay |
35 | 38.7 | 11.8 | 8.1 | 15 | OS | Age, sex, smoking, stage, co-mutations, treatment modalities (localized and systemic) | 9 |
| Cai, 2019 [44] | China | 84 | NSCLC | IV | PCR-seq | 28 | 29 | NA | 5 | NA | OS | Age, sex, ECOG PS, smoking pack years, histology, KRAS comutations | 6 |
| Cui, 2020 [45] | Australia | 346 | NSCLC | IV | NGS-PMCC lung panel mutation analysis | 19 | NA | NA | NA | 9 | OS | NA | 5 |
| Finn, 2021 [46] | Multicentric (Europe) | 2055 | NSCLC | I-III | PCR-allele-specific multiplex test | 10.5 | NA | NA | NA | 57.1 (44.3–72.3) | OS, DFS | Sex, ethnicity, smoking, age, Adj CT, Adj R.T., h/o cancer, ECOG PS, stage, primary tumor localization, tumor size, histology, surgery year, technique, and anatomy | 9 |
| Jones, 2021 [47] | USA | 604 | ADC | I-III | NGS- MSK-IMPACT | 16 | 25 | 22 | 7 | 30 (IQR 21–40) | DFS | Tumor SUVmax, DLCO, LVI, VPI, STAS, stage | 8 |
| Liu, 2020 [48] | China | 434 | NSCLC | I-IV | NGS | 9.6 | NA | NA | NA | NA | OS | Age, sex, Smoking, histology, stage, | 6 |
| Nadal, 2014 [49] | USA | 179 | ADC | I-IV | PCR-seq | 19.5 | 85 | 30.5 | NA | 95 | OS, DFS | Age, sex, stage, smoking, adjuvant therapy, tumor differentiation, | 9 |
| Osta, 2019 [50] | USA | 1655 | ADC | IV | NGS | 10.6 | 52 | 18 | NA | 25.8 | OS | Age, sex, race, smoking, ECOG PS, prior surgical/R.T. treatment, systemic therapy, KRAS comutations | 9 |
| Sebastian, 2021 [51] | Germany | 1039 | NSCLC | IIIB-IV | NGS (75%) | 15.4 | NA | NA | NA | NA | OS | Age, sex, BMI, Charlton score, ECOG PS, PD-L1 expression | 6 |
| Sun, 2013 [38] | South Korea |
304 | NSCLC | IIIB-IV | PCR-seq | 3 | NA | NA | NA | 30 | OS | NA | 6 |
| Svaton, 2016 [39] | Czechia | 129 | NSCLC | IIIB-IV | PCR-seq | 11.6 | NA | NA | NA | NA | OS | NA | 5 |
| Tao, 2020 [42] | USA | 254 | ADC | I-IV | Pyrosequencing-based test (PyroMark Q24 System; Qiagen) | 46.1 | NA | NA | NA | 17.2 (0.17–74.9) | OS, DFS | NA | 6 |
| Villacruz, 2013 [40] | USA | 318 | ADC | I-IV | PCR-seq | 43.7 | NA | NA | NA | 24.3 (0–78) | OS, DFS | NA | 6 |
| Wahl, 2021 [43] | Norway | 1117 | ADC/ADSCC | I-IV | NGS | 17 | NA | NA | NA | 52.7 (45.7–59.6) | OS | Age, sex, smoking, ECOG PS, Stage, Surgery, Curative/palliative CT/RT, TKI | 9 |
| Yu, 2015 [41] | USA | 677 | ADC | IV | Standard Sanger sequencing/ | 39 | NA | NA | NA | 17 (1–207) | OS | NA | 6 |
HR: Hazard ratio, CI: Confidence Interval NGS: Next generation sequencing, NOS: Newcastle–Ottawa Scale, PCR-seq: Polymerase chain reaction-direct nucleotide sequencing, OS: Overall survival, DFS: Disease-free survival, P.S.: performance status, Adj: adjuvant, DLCO: diffusing capacity for carbon monoxide, LVI: lymphovascular invasion, VPI: visceral pleural invasion, STAS: spread through air spaces, BMI: Body mass index, ADC: adenocarcinoma, ADSCC: adenosquamous, CT: chemotherapy, R.T.: radiotherapy, TKI: tyrosine kinase inhibitor, NA: not available, STAMP: Solid Tumor Actionable Mutational Panel.